Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Acro Biomedical (ACBM) Research & Development (2021 - 2023)

Acro Biomedical has reported Research & Development over the past 3 years, most recently at $396550.0 for Q3 2023.

  • Quarterly results put Research & Development at $396550.0 for Q3 2023, down 84.26% from a year ago — trailing twelve months through Jun 2024 was $396550.0 (down 95.8% YoY), and the annual figure for FY2023 was $4.8 million, down 52.43%.
  • Research & Development for Q3 2023 was $396550.0 at Acro Biomedical, down from $1.9 million in the prior quarter.
  • Over the last five years, Research & Development for ACBM hit a ceiling of $2.5 million in Q4 2021 and a floor of $396550.0 in Q3 2023.
  • Median Research & Development over the past 3 years was $2.5 million (2021), compared with a mean of $2.0 million.
  • Biggest five-year swings in Research & Development: skyrocketed 292.69% in 2022 and later tumbled 84.26% in 2023.
  • Acro Biomedical's Research & Development stood at $2.5 million in 2021, then changed by 0.0% to $2.5 million in 2022, then tumbled by 84.26% to $396550.0 in 2023.
  • The last three reported values for Research & Development were $396550.0 (Q3 2023), $1.9 million (Q2 2023), and $2.5 million (Q1 2023) per Business Quant data.